Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

InSphero AG. (3/16/17). "Press Release: InSphero Launches 3D InSight Monkey Liver Microtissues at Annual Society of Toxicology Meeting". Schlieren.

Region Region Baltimore, MD
  Country United States (USA)
Organisations Organisation InSphero AG
  Group InSphero (Group)
  Organisation 2 Society of Toxicology (SOT)
Products Product 3D InSight™ Monkey Liver Microtissues
  Product 2 SOT Meeting 2017 Baltimore
Persons Person Guye, Patrick (InSphero 201703 CSO)
  Person 2 Strube, Randy (InSphero 201401– Director of Global Marketing)

3D liver microtissues comprised of cynomolgus hepatocytes provide physiologically relevant in vitro model for investigating species-specific liver toxicity.

InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, today announced the launch of 3D InSight™ Monkey Liver Microtissues, further expanding the company’s suite of organotypic 3D liver models for in vitro safety and efficacy testing. Data describing the model’s characterization and application as an alternative to drug testing in animals was presented on Wednesday at the Society of Toxicology’s 56th Annual Meeting and ToxExpo in Baltimore, Maryland.

Drug-induced liver injury (DILI) remains one of the most common causes of late-stage failure in drug development and post-market drug withdrawal. Testing in non-human primates is often required to assess toxicity and potential liver-related side-effects prior to Phase I clinical trials in human patients. 3D InSight™ Monkey Liver Microtissues are a 3D spheroid liver model comprised of primary cynomolgus hepatocytes that serve as an in vitro alternative to in vivo animal tests, enabling testing species-specific effects of a drug on liver function and toxicity in preclinical studies. Viable for more than 28 days in culture, Monkey Liver Microtissues allow long-term drug exposure for predicting DILI and identifying potential mechanisms of toxicity.

InSphero Chief Scientific Officer Dr. Patrick Guye says, “Our 3D monkey liver model addresses the growing trend to reduce or replace the use of animal models in safety testing with more biologically relevant in vitro cell based models. When studies in non-human primates are still required, pre-testing in vitro can help safety and investigative toxicology groups to more effectively plan and minimize the use of costly and ethically charged animal testing. When combined with our human, rat, and dog liver models, our 3D monkey liver microtissues provide toxicologists a more complete toolbox of highly predictive human and animal-derived liver models for in vitro safety testing”

For more information about InSphero, visit

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit

Record changed: 2023-06-05


Picture [iito] [LSE] Business Portal 650x200px

More documents for InSphero (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top